Sevirumab

Sevirumab is a monoclonal antibody designed for the treatment of various infectious diseases. It is a type of biopharmaceutical that is produced using recombinant DNA technology.

History[edit | edit source]

The development of Sevirumab is part of the broader history of monoclonal antibodies in medicine. The first monoclonal antibodies were produced in the 1970s, and since then, they have become a crucial tool in both research and treatment of diseases.

Mechanism of Action[edit | edit source]

As a monoclonal antibody, Sevirumab works by binding to specific proteins on the surface of pathogens, thereby neutralizing them or marking them for destruction by the immune system. The exact target of Sevirumab depends on the disease it is designed to treat.

Production[edit | edit source]

The production of Sevirumab involves the use of recombinant DNA technology. This involves inserting the gene that codes for the antibody into a host organism, which then produces the antibody. The host organism is typically a type of yeast or bacteria.

Clinical Trials[edit | edit source]

Before Sevirumab can be approved for use in humans, it must undergo a series of clinical trials to test its safety and efficacy. These trials are typically conducted in three phases, with each phase involving a larger number of participants.

Potential Uses[edit | edit source]

Sevirumab has the potential to be used in the treatment of a wide range of infectious diseases. However, the exact diseases it can treat will depend on the results of clinical trials.